Executive Overview The landscape of haematological oncology has been fundamentally reshaped by groundbreaking immunotherapies, specifically chimeric antigen receptor (CAR) T-cell therapies and T-cell engaging bispecific antibodies (BsAbs). Approved extensively by...
Executive Overview Chimeric antigen receptor T-cell (CAR T) therapy stands as one of the most remarkable breakthroughs in...
In recent decades, the global medical community has grown accustomed to a familiar narrative regarding pediatric cholelithiasis—the presence...
Executive Overview Cutaneous T-cell lymphomas (CTCLs) represent a complex, highly heterogeneous group of lymphoproliferative neoplasms characterized by the...
Executive Overview Acute lymphoblastic leukemia (ALL) stands as the most prevalent pediatric malignancy globally, yet a profound disparity...
Executive Overview For decades, the standard management of high-risk acute promyelocytic leukemia (APL)—defined by a presenting white blood...
Published: June 10, 2026 | Frontiers in Hematology Executive Overview For more than half a century, cytotoxic chemotherapy...
Executive Overview For decades, disease relapse following allogeneic hematopoietic cell transplantation (allo-HCT) has represented one of the most...
A landmark global study has cast a long-overdue spotlight on the profound psychological, emotional, and social strain shouldered...
In the intricate landscape of hematologic oncology, thrombotic complications are a recognized, albeit dreaded, hazard. Usually emerging in...
Acute myeloid leukemia (AML) has long stood as one of the most aggressive and formidable blood cancers known...
Executive Overview Sickle cell disease (SCD) remains one of the world’s most pervasive and challenging inherited blood disorders,...
